Literature DB >> 18706263

Modern approaches to treating chronic myelogenous leukemia.

Javier Pinilla-Ibarz1, Celeste Bello.   

Abstract

Over the past decade, the treatment of chronic myelogenous leukemia (CML) has gone through significant advances. Once an invariably fatal disease without stem cell transplant, it has since become one of the most manageable hematologic malignancies with good long-term outcomes. However, patients are not cured and require life-long treatment, and unfortunately, some of these patients develop resistant disease that progresses despite our best treatments. As our understanding of CML continues to grow, the repertoire of drugs available for successful treatment also increases. The following review discusses the current and future therapies for CML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706263     DOI: 10.1007/s11912-008-0057-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  33 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

Review 2.  Mitotic kinases as regulators of cell division and its checkpoints.

Authors:  E A Nigg
Journal:  Nat Rev Mol Cell Biol       Date:  2001-01       Impact factor: 94.444

3.  Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.

Authors:  J M Rojas; K Knight; L Wang; R E Clark
Journal:  Leukemia       Date:  2007-07-19       Impact factor: 11.528

4.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

5.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

6.  Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors:  Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal:  Science       Date:  2004-07-16       Impact factor: 47.728

7.  A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.

Authors:  Kathleen Cathcart; Javier Pinilla-Ibarz; Tatyana Korontsvit; Joseph Schwartz; Victoriya Zakhaleva; Esperanza B Papadopoulos; David A Scheinberg
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 8.  WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Olga A Elisseeva; Hiroko Nakajima; Fumihiro Fujiki; Manabu Kawakami; Toshiaki Shirakata; Sumiyuki Nishida; Naoki Hosen; Yusuke Oji; Ichiro Kawase; Haruo Sugiyama
Journal:  ScientificWorldJournal       Date:  2007-05-29

9.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Authors:  Thomas O'Hare; Denise K Walters; Eric P Stoffregen; Taiping Jia; Paul W Manley; Jürgen Mestan; Sandra W Cowan-Jacob; Francis Y Lee; Michael C Heinrich; Michael W N Deininger; Brian J Druker
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

10.  BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

Authors:  Mhairi Copland; Francesca Pellicano; Linda Richmond; Elaine K Allan; Ashley Hamilton; Francis Y Lee; Roberto Weinmann; Tessa L Holyoake
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

View more
  4 in total

1.  Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010.

Authors:  Shweta Bansal; S H Advani
Journal:  Indian J Med Paediatr Oncol       Date:  2013-07

2.  Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years.

Authors:  Rajesh P Dikshit; Rajini Nagrani; Balkrishna Yeole; Shravani Koyande; Shripad Banawali
Journal:  Indian J Med Paediatr Oncol       Date:  2011-04

Review 3.  Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.

Authors:  Fei Xiong; Qi Wang; Guan-Hua Wu; Wen-Zheng Liu; Bing Wang; Yong-Jun Chen
Journal:  Biomark Res       Date:  2022-09-14

4.  Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.

Authors:  Kazuya Sumi; Kenji Tago; Yosuke Nakazawa; Kyoko Takahashi; Tomoyuki Ohe; Tadahiko Mashino; Megumi Funakoshi-Tago
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.